If you take duloxetine — the generic form of the antidepressant Cymbalta — check the lot number on your bottle right now.
Breckenridge Pharmaceutical, Inc. has voluntarily recalled multiple lots of duloxetine delayed-release capsules after laboratory testing found levels of a chemical called N-nitroso-duloxetine above the FDA's acceptable daily intake limit. N-nitroso-duloxetine is a nitrosamine compound — a class of substances classified as probable human carcinogens, meaning that repeated long-term exposure above safe levels may increase cancer risk over time.
According to ABC News, NBC New York, and the FDA's enforcement database, this recall is underway and ongoing. The pills were manufactured by Towa Pharmaceutical Europe in Spain and distributed in the United States by Breckenridge.
The most important message for patients: do not stop taking duloxetine without first speaking to your doctor or pharmacist. Abruptly stopping this medication can cause serious withdrawal effects. Contact your prescriber to arrange a safe replacement from a non-recalled lot.
Why This Matters
Duloxetine (brand name: Cymbalta) is one of the most widely prescribed psychiatric and pain medications in the United States. It is an SNRI (serotonin-norepinephrine reuptake inhibitor) used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, chronic musculoskeletal pain, and diabetic peripheral neuropathy. Millions of Americans take it daily.
The specific concern here is not acute toxicity — the FDA has classified this as a Class II recall, meaning the product "may cause temporary or medically reversible adverse health consequences." There are no confirmed cancer cases associated with this specific recall. The FDA notes explicitly that people exposed to nitrosamine impurities "at or below the acceptable daily intake limit are not expected to have an increased risk of cancer."
The concern is about elevated levels — above the FDA's interim limit — and the risk that may result from prolonged exposure at those elevated levels. This is the same type of contamination that triggered major recalls of blood pressure drugs like valsartan and losartan in 2018 and 2019, and the heartburn drug Zantac in 2019.
The Specific Recalled Products and Lot Numbers
According to the California Board of Pharmacy's published recall notice from Breckenridge and reporting from KVUE and King5:
30mg Duloxetine Delayed-Release Capsules:
- NDC: 51991-747-10 (1,000-count bottles)
- Lot 241180C, Expiration: April 2027
- Approximately 14,729 bottles affected
60mg Duloxetine Delayed-Release Capsules — Multiple lots affected, including:
- NDC: 51991-748-10 (1,000-count bottles) — Lot 240987C, Exp. April 2027
- NDC: 51991-748-10 — Lot 241014C, Exp. April 2027
- Additional lots: Lot 230286C (Exp. February 2026) and Lot 240721C (Exp. February 2027), distributed primarily via the California supply chain
- 90-count bottles (NDC: 51991-748-90): Lot 230201C (Exp. January 2026) also included in earlier notices
The recall is described as ongoing, and additional lot numbers may be added as Breckenridge continues its quality assessment. Breckenridge has stated this is a Retail Level Recall, meaning it should be carried out back through pharmacy stock.
To verify the most current complete list, check the FDA Drug Recalls database at FDA.gov/drugs/drug-safety-and-availability/drug-recalls and search for "duloxetine" and "Breckenridge."
What Nitrosamines Are and How This Happened
Nitrosamines are a class of chemical compounds — some of which are classified as probable human carcinogens by the International Agency for Research on Cancer. N-nitroso-duloxetine is the nitrosamine compound specifically associated with duloxetine's chemical structure; it forms when a nitrogen atom in the drug molecule reacts with nitrosating agents, a reaction that can occur during certain manufacturing conditions, interactions with raw materials, storage, or packaging changes.
As Pharmaceutical Technology noted in its analysis, "nitrosamine risk assessments are no longer a one-time regulatory exercise tied to a single product launch; they require ongoing scrutiny whenever raw material sources, synthetic routes, or storage conditions change." The FDA has required manufacturers across the pharmaceutical industry to assess nitrosamine risk in their products since 2020, but these assessments are ongoing and some contamination issues are only detected during post-market testing.
There are no confirmed human cases of cancer linked directly to N-nitroso-duloxetine specifically — the carcinogen classification is based on the compound's chemical structure and behavior in animal studies, not confirmed human clinical outcomes at the levels found in this recall.
What Doctors and Experts Say
Breckenridge's recall notice confirms that no adverse events assessed to be related to this recall have been reported to date. The FDA's Class II designation reflects the agency's view that the most likely adverse health consequences would be temporary or medically reversible, not life-threatening.
Pharmacists and physicians responding to similar past nitrosamine recalls consistently emphasize two points: first, the risk from past exposure at these elevated levels is statistically very low — the FDA's acceptable daily intake limit is set with significant safety margins — and second, the greatest immediate risk patients face is from abruptly stopping a psychiatric medication without medical guidance.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Contaminant: N-nitroso-duloxetine (a nitrosamine compound)
- Risk: Classified as a probable human carcinogen based on chemical class and animal data
- Confirmed human cancer cases from this recall: None reported as of the recall date
- FDA classification: Class II — may cause temporary or medically reversible adverse health consequences
- What this does not mean: That patients who took recalled lots have definitively been harmed or will develop cancer
Who Is Most Affected?
- Anyone who currently takes generic duloxetine distributed by Breckenridge Pharmaceutical and fills prescriptions at pharmacies that stock this manufacturer's product
- Patients who have been taking the affected lots for weeks to months, given that the carcinogen risk is associated with prolonged exposure above the limit, not short-term exposure
- People taking 30mg or 60mg delayed-release capsules (not 20mg) from Breckenridge/Towa
What You Can Do Now
- Check the NDC number, lot number, and expiration date on your duloxetine bottle against the recalled lots listed above.
- If your bottle matches a recalled lot, do NOT stop taking your medication. Contact your doctor or pharmacist immediately to arrange a replacement from a non-recalled lot — pharmacies can dispense from a different manufacturer.
- Your pharmacist can check whether the duloxetine they currently stock is from Breckenridge's recalled lots and substitute a different manufacturer's product.
- Report any concerns or adverse events to the FDA's MedWatch program at accessdata.fda.gov/scripts/medwatch .
- For full current lot information, visit FDA.gov/drugs/drug-safety-and-availability/drug-recalls .
Cost and Access: What Patients Should Know
Pharmacies should be able to substitute duloxetine from a different, non-recalled manufacturer at no additional cost if you are on a standard formulary. If you have concerns about out-of-pocket cost differences between manufacturers, ask your pharmacist about equivalents. If you are on a fixed income or lack insurance, patient assistance programs exist for generic medications — your pharmacist can advise on current options.
The Bottom Line
A voluntary recall of duloxetine (generic Cymbalta) has been initiated due to elevated levels of a nitrosamine, a probable carcinogen, above the FDA's accepted limit. The recalled lots include 30mg capsules (Lot 241180C, Exp. April 2027) and multiple lots of 60mg capsules. There are no confirmed cancer cases from this recall. The most important action: check your lot numbers, contact your pharmacist or doctor, and do NOT stop taking duloxetine abruptly — that carries its own serious risks that outweigh the low-level long-term cancer concern this recall addresses.
